Helle Toldbod

1.2k citations
13 papers · 804 indexed · h-index 9

Impact in

Papers in

Helle Toldbod

13 papers receiving 793 citations

Peers

Helle Toldbod
Comparison fields: 5 of 46
  • Pathology and Forensic Medicine 513
  • Dermatology 139
  • Oncology 405
  • Genetics 145
  • Immunology 244
Replace Feifei Nan with:
Feifei Nan China
Julia Steinhilber Germany
Chengfeng Bi China
Anna Gazzola Italy
Annette M. Staiger Germany
C Lavignac France
Marolleau Jp France
Maria Delioukina United States
Alejandra Martínez‐Trillos Spain
Harish K. Gagneja United States
Helle Toldbod relative to Feifei Nan China Feifei Nan's profile →
Citations per field
00.5×3.5×
Feifei Nan · 1×
Citations per year

Countries citing papers authored by Helle Toldbod

Since Specialization
Citations

This map shows the geographic impact of Helle Toldbod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helle Toldbod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helle Toldbod more than expected).

Fields of papers citing papers by Helle Toldbod

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helle Toldbod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helle Toldbod. The network helps show where Helle Toldbod may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Helle Toldbod, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Helle Toldbod Line = papers co-authored together Helle Toldbod links everyone, so they are left out of the graph.

All Works

13 of 13 papers shown
#Work
1 201916
2 2018100
3 201813
4 20175
5 201615
6 20161
7 20145
8 2012386
9
Upfront Autologuos Stem Cell Transplantation in Peripheral T-cell Lymphoma (NLG-T-01)
20121
10 20118
11 201056
12 2007167
13 200331

About Helle Toldbod

Helle Toldbod is a scholar working on Pathology and Forensic Medicine, Oncology, Genetics, Immunology and Urology, having authored 13 papers that have together received 804 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (10 papers), T-cell and Retrovirus Studies (4 papers), CAR-T cell therapy research (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Bladder and Urothelial Cancer Treatments (2 papers), vaccines and immunoinformatics approaches (1 paper), Viral-associated cancers and disorders (1 paper) and CNS Lymphoma Diagnosis and Treatment (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (513 citations), Dermatology (139 citations), Oncology (405 citations), Genetics (145 citations) and Immunology (244 citations). Helle Toldbod has collaborated with scholars based in Denmark, Finland and Sweden. Frequent co-authors include Francesco d’Amore, Thomas Relander, Jan Delabie, Torben F. Ørntoft, Lars Dyrskjøt, Francisco Mansilla, Hans Hagberg, Outi Kuittinen, Peter de Nully Brown and Elisabeth Ralfkiær. Their work appears in journals such as Blood, Scandinavian Journal of Immunology, Journal of Clinical Oncology, Clinical Cancer Research and Annals of Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026